| Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ... Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021 | 91 | 2021 |
| HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis JP Alderuccio, AJ Olszewski, AM Evens, GP Collins, AV Danilov, M Bower, ... Blood advances 5 (14), 2852-2862, 2021 | 36 | 2021 |
| Capecitabine for the treatment of pancreatic cancer NS Siddiqui, A Godara, MM Byrne, MW Saif Expert opinion on pharmacotherapy 20 (4), 399-409, 2019 | 36 | 2019 |
| Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study AS Zayac, AM Evens, A Danilov, SD Smith, D Jagadeesh, LA Leslie, ... Haematologica 106 (7), 1932, 2021 | 29 | 2021 |
| Length of stay and hospital costs for patients undergoing allogeneic stem-cell transplantation A Godara, NS Siddiqui, S Munigala, R Dhawan, AJ Kansagra, ... JCO oncology practice 17 (3), e355-e368, 2021 | 28 | 2021 |
| Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 … H Hachem, A Godara, C Schroeder, D Fein, H Mann, C Lawlor, J Marshall, ... Journal of Clinical and Translational Science 5 (1), e146, 2021 | 27 | 2021 |
| Association between spinal stenosis and wild-type ATTR amyloidosis A Godara, RI Riesenburger, DX Zhang, C Varga, T Fogaren, NS Siddiqui, ... Amyloid 28 (4), 226-233, 2021 | 26 | 2021 |
| Dual monoclonal antibody therapy in patients with systemic AL amyloidosis and cardiac involvement A Godara, NS Siddiqui, LX Lee, D Toskic, T Fogaren, C Varga, ... Clinical Lymphoma Myeloma and Leukemia 20 (3), 184-189, 2020 | 22 | 2020 |
| Increased thickness of lumbar spine ligamentum flavum in wild-type transthyretin amyloidosis KM George, NS Hernandez, J Breton, B Cooper, RS Dowd, J Nail, A Yu, ... Journal of Clinical Neuroscience 84, 33-37, 2021 | 16 | 2021 |
| Outcomes of patients with newly-diagnosed Burkitt lymphoma (BL) and central nervous system (CNS) involvement treated in the modern era: A multi-institutional real-world analysis A Zayac, AM Evens, A Stadnik, SD Smith, D Jagadeesh, LA Leslie, C Wei, ... Blood 134, 402, 2019 | 14 | 2019 |
| The safety of lanreotide for neuroendocrine tumor A Godara, NS Siddiqui, MM Byrne, MW Saif Expert opinion on drug safety 18 (1), 1-10, 2019 | 13 | 2019 |
| Presence of soluble and cell-surface B-cell maturation antigen in systemic light-chain amyloidosis and its modulation by gamma-secretase inhibition A Godara, P Zhou, A Kugelmass, X Ma, B Rosenthal, D Toskic, T Fogaren, ... American journal of hematology 95 (5), E110-E113, 2020 | 12 | 2020 |
| Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma Y Zhang, A Godara, S Pan, D Toskic, H Mann, D Sborov, R Comenzo, ... Annals of Hematology 101 (9), 2119-2121, 2022 | 11 | 2022 |
| Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels KM George, NS Hernandez, J Breton, B Cooper, RS Dowd, J Nail, A Yu, ... Clinical Neurology and Neurosurgery 206, 106708, 2021 | 8 | 2021 |
| Monoclonal antibody therapies in systemic light-chain amyloidosis A Godara, G Palladini Hematology/Oncology Clinics 34 (6), 1145-1159, 2020 | 8 | 2020 |
| Pharmacogenetic variants in the DPYD and TYMS genes are clinically significant predictors of fluoropyrimidine toxicity: are we ready for use in our clinical practice MW Saif, H Hachem, S Purvey, R Hamal, L Zhang, NS Siddiqui, A Godara, ... Archives of pharmacology and therapeutics 2 (1), 6, 2020 | 8 | 2020 |
| In systemic light-chain amyloidosis complete and very good partial responses are not enough: involved free light chain (iFLC) levels< 10mg/L are associated with optimal long … A Godara, D Toskic, B Rosenthal, C Varga, A Kugelmass, P Zhou, ... Blood 134, 4369, 2019 | 8 | 2019 |
| A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseases X Ma, P Zhou, A Kugelmass, D Toskic, M Warner, L Lee, T Fogaren, ... Gene Therapy 26 (5), 187-197, 2019 | 8 | 2019 |
| B-cell maturation antigen (BCMA) in systemic light-chain amyloidosis (AL): association with disease activity and its modulation with gamma-secretase inhibition A Godara, P Zhou, B Rosenthal, A Kugelmass, D Toskic, T Fogaren, ... Blood 134, 4409, 2019 | 6 | 2019 |
| Supervised machine learning algorithms using patient related factors to predict in-hospital mortality following acute myeloid leukemia therapy NS Siddiqui, A Klein, A Godara, C Varga, RJ Buchsbaum, MC Hughes Blood 134, 3435, 2019 | 6 | 2019 |
